Effects of botulinum toxin type A in Meige's syndrome

Background: Meige ’s syndrome (MS) is a type of facial dystonia characterized by the simultaneous occurrence of blepharospasm and oromandibular dystonia. It was first described in 1910, by dr. Henri Meige, a French neurologist. Since then, MS physiopathology was not completely identified. It is known that genetic f actors, as well as environmental triggers, are involved in changes in the dopaminergic system modulation, causing hyperactivation of certain regions of the nervous system, such as the hypothalamus and basal ganglia.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Source Type: research